Theorem Clinical Research

Drug Sponsors

Kite Pharma acquires T-Cell Factory for $21M

Wednesday, March 18, 2015 01:14 PM

Kite Pharma, a Santa Monica, Calif.-based, clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on CAR and TCR gene therapy platforms for the treatment of cancer, acquired T-Cell Factory (TCF), a privately held Dutch company, which has been renamed Kite Pharma E.U.

More... »

Quest Diagnostics

New immunotechnology center MI-mAbs launched

Monday, March 16, 2015 01:48 PM

MI-mAbs, a new immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory disease and founding member of the France-based Marseille Immunopole (MI) cluster, has announced the signature of the consortium agreement sealing the commitment of its founders: Aix-Marseille Universite (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC); three of their research centers (the Centre d'Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Center for Immunophenomics); Innate Pharma, a European immuno-oncology company; and Sanofi.

More... »


Ruthigen, Pulmatrix ink merger agreement

Monday, March 16, 2015 01:41 PM

Ruthigen, a biopharmaceutical company based in Santa Rosa, Calif., and Pulmatrix, a Lexington, Mass.-based clinical stage biotech, have entered into a definitive merger agreement. Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix's debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen.

More... »

Par Pharmaceutical files for IPO

Friday, March 13, 2015 12:55 PM

Par Pharmaceutical Holdings has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered by Par Pharmaceutical and its shareholders, and the price range for the offering, have not yet been determined.

More... »

Ember, Mariel Therapeutics ink merger agreement

Friday, March 13, 2015 12:33 PM

Ember Therapeutics, a Boston-based biotech discovering and developing novel obesity and diabetic related therapies, will merge with Mariel Therapeutics, a privately held, New York-based biotech developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7.

More... »

GSK establishes Asian global headquarters in Singapore

Thursday, March 12, 2015 01:00 PM

GlaxoSmithKline is strengthening its presence in Singapore by establishing a new global headquarters for Asia, further expanding its commitment to patients and consumers in the region.

More... »

Endo bids to acquire Salix for $11 billion

Thursday, March 12, 2015 12:58 PM

Raleigh, N.C.-based Salix Pharmaceuticals has received an unsolicited proposal from Endo International, a global specialty healthcare company headquartered in Dublin, Ireland, to acquire all outstanding shares of common stock of the company for a combination of 1.4607 shares of Endo common stock and $45 cash per share of common stock. Based on the closing stock price of Endo on March 10, 2015, the transaction is valued at $175 per Salix share. 

More... »

Impax completes acquisition of Tower Holdings and Lineage Therapeutics

Wednesday, March 11, 2015 12:43 PM

Impax Laboratories, a pharmaceutical company headquartered in Hayward, Calif., has completed its acquisition of Tower Holdings (including operating subsidiaries CorePharma and Amedra Pharmaceuticals), and Lineage Therapeutics.

More... »

PharmAthene to cut two-thirds of staff

Wednesday, March 11, 2015 12:32 PM

Annapolis, Md.-based PharmAthene will launch a realignment plan that includes reducing its staffing levels by approximately two-thirds. Eric Richman, president and CEO, will remain a member of the board of directors but will no longer serve as an officer of the company, effective March 11. He will continue to play a key role in managing the ongoing litigation, other legal matters and strategic transactions in his role as director.

More... »

Concordia Healthcare to acquire Covis Pharma commercial assets for $1.2B

Wednesday, March 11, 2015 12:28 PM

Concordia Healthcare, a Canada-based diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population, will acquire substantially all of the commercial assets of privately held Covis Pharma and Covis Injectables, headquartered in Zug, Switzerland, for $1.2 billion in cash.

More... »

AiCure
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs